Neuroxt And BIDMC Join Forces To Revolutionize Alzheimer's Treatment With AI

New Partnership Aims to Tailor Alzheimer's Treatments Using Cutting-Edge AI Technology

BOSTON, Aug. 22, 2024 /PRNewswire/ -- In a groundbreaking move that could transform Alzheimer's treatment, NeuroXT, a leading biotechnology startup, has partnered with Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital affiliated with Harvard Medical School. Together, they are set to revolutionize how Alzheimer's is treated by developing AI-driven imaging biomarker solutions that predict treatment success.

With recent FDA approvals of promising Alzheimer's drugs like Eisai's Leqembi and Eli Lilly's Kisunla, there is renewed hope in the fight against this challenging disease. However, these treatments are not without their hurdles—ranging from inconsistent results to potential side effects. NeuroXT aims to overcome these obstacles by harnessing the power of AI to deliver personalized treatment strategies.

NeuroXT's state-of-the-art technology uses MRI data to understand the interaction between beta-amyloid and tau proteins—key players in Alzheimer's disease. This innovative approach has the potential to tailor treatment plans to each patient, dramatically improving outcomes and minimizing side effects.

This research, led by Daniel Press, MD, Chief of the Cognitive Neurology Unit at Beth Israel Deaconess Medical Center, aims to enhance treatment effectiveness and proactively improve treatment monitoring, including amyloid reduction monitoring and Amyloid-Related Imaging Abnormalities (ARIA) side effects, a common concern in recent trials.

About NeuroXT

NeuroXT is at the forefront of biotechnology, focusing on AI-driven solutions for neurological conditions. Under the leadership of CEO Sung Joon-kyung, NeuroXT is committed to advancing Alzheimer's treatment through precision medicine. Their cutting-edge AI imaging biomarker technology is designed to predict individual treatment responses, ensuring the best therapeutic window for each patient.

Contact:
Martin Hyun
NeuroXT
808-354-9669
382148@email4pr.com

For more details on NeuroXT's AI-driven innovations and its partnership with BIDMC, visit www.neuroxt.com or contact us directly.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroxt-and-bidmc-join-forcesto-revolutionize-alzheimers-treatment-with-ai-302227444.html

SOURCE NeuroXT

First published on Fri, Aug 23, 2024

Enjoyed what you've read so far? Great news - there's more to explore!

Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.

Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.

Dive into TechDogs' treasure trove today and Know Your World of technology!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

Alzheimer's AI Biotechnology NeuroXT BIDMC Treatment Imaging Biomarkers

Join The Discussion

- Promoted By TechDogs -

Biotechnology